Virtus ETF Advisers LLC Has $113,000 Holdings in Precigen, Inc. (NASDAQ:PGEN)

Virtus ETF Advisers LLC lessened its stake in Precigen, Inc. (NASDAQ:PGENFree Report) by 9.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,754 shares of the biotechnology company’s stock after selling 7,938 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Precigen were worth $113,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sanders Morris Harris LLC raised its stake in Precigen by 26.2% in the third quarter. Sanders Morris Harris LLC now owns 410,000 shares of the biotechnology company’s stock valued at $582,000 after purchasing an additional 85,000 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in Precigen by 1,092.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 52,272 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 47,888 shares during the last quarter. Principal Financial Group Inc. grew its position in Precigen by 34.7% in the second quarter. Principal Financial Group Inc. now owns 65,326 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 16,833 shares during the last quarter. Magnolia Capital Advisors LLC bought a new position in Precigen in the third quarter valued at about $57,000. Finally, SG Americas Securities LLC bought a new position in Precigen in the third quarter valued at about $96,000. Institutional investors and hedge funds own 22.48% of the company’s stock.

Insider Transactions at Precigen

In other news, Director Randal J. Kirk purchased 96,686 shares of Precigen stock in a transaction dated Thursday, December 28th. The shares were bought at an average cost of $1.41 per share, for a total transaction of $136,327.26. Following the completion of the acquisition, the director now owns 1,096,686 shares in the company, valued at approximately $1,546,327.26. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 41.70% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Precigen to a “sell” rating in a research report on Wednesday.

Get Our Latest Research Report on Precigen

Precigen Trading Down 0.7 %

Precigen stock opened at $1.39 on Friday. Precigen, Inc. has a 12-month low of $0.81 and a 12-month high of $2.01. The business’s 50-day moving average price is $1.28 and its two-hundred day moving average price is $1.32.

Precigen (NASDAQ:PGENGet Free Report) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $1.38 million for the quarter, compared to analysts’ expectations of $2.68 million. Precigen had a negative return on equity of 54.48% and a negative net margin of 1,257.75%. As a group, equities research analysts forecast that Precigen, Inc. will post -0.34 EPS for the current year.

About Precigen

(Free Report)

Precigen, Inc discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies.

Further Reading

Want to see what other hedge funds are holding PGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Precigen, Inc. (NASDAQ:PGENFree Report).

Institutional Ownership by Quarter for Precigen (NASDAQ:PGEN)

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.